MicroRNA hsa-miR-134 is a circulating biomarker for mesial temporal lobe epilepsy

Area of Science:

• Neuroscience
• Biomarker Discovery
• Molecular Diagnostics

Background:

• Epilepsy misdiagnosis affects up to 25% of patients, leading to significant adverse outcomes.
• Circulating microRNAs show promise as diagnostic biomarkers in various diseases.
• Accurate epilepsy diagnosis is crucial for effective treatment and patient management.

Purpose of the Study:

• To identify and validate circulating microRNAs as potential diagnostic biomarkers for epilepsy.
• To investigate the role of hsa-miR-134 in distinguishing mesial temporal lobe epilepsy (MTLE) from controls and other epilepsy types.

Main Methods:

• Quantitative real-time PCR was employed to measure plasma microRNA levels.
• A two-phase study design included discovery and validation cohorts.
• Candidate microRNAs were analyzed in patients with MTLE, focal cortical dysplasia (FCD), and healthy controls.

Main Results:

• Hsa-miR-134 was significantly downregulated in MTLE patients compared to controls (p = 0.018 in discovery, p < 0.001 in validation).
• Hsa-miR-134 demonstrated potential in discriminating MTLE patients (AUC = 0.75).
• Downregulated hsa-miR-134 was observed irrespective of pharmacotherapy response or MRI findings.

Conclusions:

• Decreased plasma hsa-miR-134 levels represent a potential non-invasive biomarker for supporting MTLE diagnosis.
• Hsa-miR-134 may help improve diagnostic accuracy and reduce misdiagnosis rates in epilepsy.
• This microRNA biomarker holds promise for clinical application in epilepsy diagnostics.